JP2004534741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534741A5 JP2004534741A5 JP2002576291A JP2002576291A JP2004534741A5 JP 2004534741 A5 JP2004534741 A5 JP 2004534741A5 JP 2002576291 A JP2002576291 A JP 2002576291A JP 2002576291 A JP2002576291 A JP 2002576291A JP 2004534741 A5 JP2004534741 A5 JP 2004534741A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- fragment
- cancer
- antibody
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR3958A AUPR395801A0 (en) | 2001-03-26 | 2001-03-26 | Antibodies against cancer |
| AUPR3958 | 2001-03-26 | ||
| PCT/AU2002/000362 WO2002077033A1 (en) | 2001-03-26 | 2002-03-26 | Antibodies against cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008188842A Division JP2009024014A (ja) | 2001-03-26 | 2008-07-22 | 癌に対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534741A JP2004534741A (ja) | 2004-11-18 |
| JP2004534741A5 true JP2004534741A5 (enExample) | 2005-12-22 |
| JP4854912B2 JP4854912B2 (ja) | 2012-01-18 |
Family
ID=3827964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002576291A Expired - Fee Related JP4854912B2 (ja) | 2001-03-26 | 2002-03-26 | 癌に対する抗体 |
| JP2008188842A Pending JP2009024014A (ja) | 2001-03-26 | 2008-07-22 | 癌に対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008188842A Pending JP2009024014A (ja) | 2001-03-26 | 2008-07-22 | 癌に対する抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7318924B2 (enExample) |
| EP (1) | EP1383801A4 (enExample) |
| JP (2) | JP4854912B2 (enExample) |
| KR (1) | KR100909290B1 (enExample) |
| CN (2) | CN101310770A (enExample) |
| AU (3) | AUPR395801A0 (enExample) |
| CA (1) | CA2442318A1 (enExample) |
| NZ (1) | NZ528624A (enExample) |
| WO (1) | WO2002077033A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| HUP0501113A3 (en) * | 2001-04-26 | 2007-12-28 | Biogen Idec Inc | Cripto blocking antibodies and uses thereof |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| CA2502681A1 (en) * | 2002-10-23 | 2004-05-06 | Exelixis, Inc. | Mbms as modifiers of branching morphogenesis and methods of use |
| WO2004090158A1 (ja) * | 2003-04-03 | 2004-10-21 | Oncorex, Inc. | 医薬品 |
| US20050163782A1 (en) * | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
| US7820620B2 (en) * | 2003-09-15 | 2010-10-26 | Research Development Foundation | Cripto antagonism of activin and TGF-b signaling |
| EP2591786B1 (en) | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| EP2311880A3 (en) * | 2005-01-05 | 2011-07-27 | Biogen Idec MA Inc. | Cripto binding molecules |
| US7939056B2 (en) * | 2005-11-14 | 2011-05-10 | The Brigham And Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
| CA2688563A1 (en) * | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
| CA2728739C (en) | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| KR100973029B1 (ko) * | 2008-10-07 | 2010-08-11 | 박지운 | 알루미늄 합금 가로등 등주 |
| JP5805538B2 (ja) * | 2008-11-07 | 2015-11-04 | リサーチ ディベロップメント ファウンデーション | Ｃｒｉｐｔｏ／ＧＳＰ７８複合体形成およびシグナル伝達を阻害するための組成物および方法 |
| WO2012105219A1 (ja) * | 2011-01-31 | 2012-08-09 | オリンパス株式会社 | 抗体療法の効果増強剤 |
| AU2012244673A1 (en) | 2011-04-21 | 2013-11-28 | Seattle Genetics, Inc. | Novel binder-drug conjugates (ADCs) and their use |
| CN106163568B (zh) | 2013-12-23 | 2021-03-23 | 拜耳制药股份公司 | 含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc） |
| CA2983311A1 (en) * | 2015-04-20 | 2016-10-27 | Minomic International Ltd. | Therapeutic antibodies and uses thereof |
| EP3310440A1 (de) | 2015-06-22 | 2018-04-25 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen |
| HK1246717A1 (zh) | 2015-06-23 | 2018-09-14 | Bayer Pharma Aktiengesellschaft | Ksp抑制剂的靶向缀合物 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| JP7022707B2 (ja) | 2016-06-15 | 2022-02-18 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ） |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| PE20191235A1 (es) | 2016-12-21 | 2019-09-11 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente |
| CN109744199A (zh) * | 2017-11-08 | 2019-05-14 | 南京艾莫瑞生物科技有限公司 | 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用 |
| JP6761889B1 (ja) * | 2019-11-11 | 2020-09-30 | 株式会社Ｇｓｐエンタープライズ | 抗ヒトＣｒｉｐｔｏ−１抗体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5171665A (en) | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
| US5256643A (en) * | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| US5264557A (en) * | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
| US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
| KR20000015893A (ko) | 1996-05-22 | 2000-03-15 | 댄 마이클 | 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도 |
| IL125608A0 (en) * | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| ID29246A (id) * | 1999-03-11 | 2001-08-16 | Ardenia Investments Ltd | Senyawa-senyawa baru untuk pengobatan kanker |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| WO2002022808A2 (en) | 2000-09-18 | 2002-03-21 | Biogen, Inc. | Cripto mutant and uses thereof |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| HUP0501113A3 (en) | 2001-04-26 | 2007-12-28 | Biogen Idec Inc | Cripto blocking antibodies and uses thereof |
-
2001
- 2001-03-26 AU AUPR3958A patent/AUPR395801A0/en not_active Abandoned
-
2002
- 2002-03-26 WO PCT/AU2002/000362 patent/WO2002077033A1/en not_active Ceased
- 2002-03-26 NZ NZ528624A patent/NZ528624A/xx not_active IP Right Cessation
- 2002-03-26 CA CA002442318A patent/CA2442318A1/en not_active Abandoned
- 2002-03-26 CN CNA2008101103851A patent/CN101310770A/zh active Pending
- 2002-03-26 AU AU2002240719A patent/AU2002240719B2/en not_active Ceased
- 2002-03-26 CN CNB028073177A patent/CN100457781C/zh not_active Expired - Fee Related
- 2002-03-26 US US10/470,013 patent/US7318924B2/en not_active Expired - Fee Related
- 2002-03-26 EP EP02706533A patent/EP1383801A4/en not_active Withdrawn
- 2002-03-26 JP JP2002576291A patent/JP4854912B2/ja not_active Expired - Fee Related
-
2003
- 2003-09-26 KR KR1020037012528A patent/KR100909290B1/ko not_active Expired - Fee Related
-
2007
- 2007-04-11 AU AU2007201587A patent/AU2007201587A1/en not_active Abandoned
-
2008
- 2008-07-22 JP JP2008188842A patent/JP2009024014A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534741A5 (enExample) | ||
| Pinto et al. | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) | |
| AU2019396895B2 (en) | Combination of antibody-drug conjugate with PARP inhibitor | |
| Singh et al. | Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer | |
| JP2008531576A5 (enExample) | ||
| Sirotnak et al. | Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase | |
| HRP20151257T1 (hr) | Monoklonska protutijela na klaudin-18 za lijeäśenje karcinoma | |
| JP2008528486A5 (enExample) | ||
| NZ528624A (en) | Antibodies against cancer | |
| Park et al. | A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma | |
| JP2009505676A5 (enExample) | ||
| JP2018534933A5 (enExample) | ||
| RU2005132788A (ru) | Способ лечения рака у человека (варианты), применяемая в способе форма (варианты) и применение антитела (варианты) | |
| SI2719708T1 (en) | Material and methods for treating or preventing HER-3-related diseases | |
| JP2010535713A5 (enExample) | ||
| RU2007101378A (ru) | Терапия злокачественной опухоли, резистентной к препаратам на основе платины | |
| JP2008503476A5 (enExample) | ||
| Aoki et al. | Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective | |
| JP2007513073A5 (enExample) | ||
| JP2015508280A5 (enExample) | ||
| JP2011512332A5 (enExample) | ||
| ME02296B (me) | Postupak za liječenje kancera dll4 antagonistom i hemoterapijskim agensom | |
| RU2020115713A (ru) | Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения | |
| JP2009522316A5 (enExample) | ||
| Lu et al. | Exploring the therapeutic potential of ADC combination for triple-negative breast cancer |